(Q83067930)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21193114%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

Factor Xa and thrombin as targets for new oral anticoagulants (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21193114%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1

Jeffrey I Weitz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21193114%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

1 January 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21193114%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21193114%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

127 Suppl 2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21193114%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

S5-S12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21193114%20AND%20SRC:MED&resulttype=core&format=json

Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry

19 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

What is all that thrombin for?

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

Direct thrombin inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

Comparison of fondaparinux and enoxaparin in acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

The use of prothrombin(S525C) labeled with fluorescein to directly study the inhibition of prothrombinase by antithrombin during prothrombin activation

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

Factor Xa is highly protected from antithrombin-fondaparinux and antithrombin-enoxaparin when incorporated into the prothrombinase complex

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

Cofactor proteins in the assembly and expression of blood clotting enzyme complexes

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

1 reference

7 January 2021

Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood [...]

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

Dabigatran versus warfarin in the treatment of acute venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

Dabigatran versus warfarin in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM).

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

New oral anticoagulants in development.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

1 reference

7 January 2021

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970147-X

7 January 2021

10.1016/S0049-3848(10)70147-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21193114%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference